Filing Flows › Bio-Techne (TECH) › Q4 FY26 › vs Q4 FY25
Bio-Techne (TECH) Q4 FY26 vs Q4 FY25 (year over year)
Bio-Techne's revenue rose $4.2M (+1%) from $317M in Q4 FY25 to $321M in Q4 FY26. Gross margin 65.8% against 62.7% (+3.1 pts).
Bio-Techne, Q4 FY26: revenue $321M (+1% year over year), operating margin 23.1%, net earnings $54.6M, operating cash flow $95.4M. The chart draws each line against Q4 FY25, the increases inside each band.
Margins
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Gross margin | 65.8% | 62.7% | +3.1 pts |
| Operating margin | 23.1% | -7.5% | +30.7 pts |
| Net margin | 17.0% | -5.6% | +22.6 pts |
| Free cash flow margin | 27.1% | 29.4% | -2.4 pts |
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $321M | $317M | $4.2M | +1% |
| Gross profit | $211M | $199M | $12.6M | +6% |
| Cost of revenue | $110M | $118M | −$8.4M | -7% |
| Operating profit | $74.3M | −$23.9M | $98.1M | — |
| Operating expenses | $137M | $223M | −$85.6M | -38% |
| Pre-tax earnings | $70.7M | −$22.9M | $93.5M | — |
| Other expense, net | $3.6M | −$1.0M | $4.6M | — |
| Research & development | $23.9M | $26.0M | −$2.1M | -8% |
| SG&A | $113M | $197M | −$83.5M | -42% |
| Net earnings | $54.6M | −$17.7M | $72.3M | — |
| Income tax | $16.1M | −$5.2M | $21.2M | — |
| Depreciation & amortization | $24.1M | $27.1M | −$3.0M | -11% |
| Share-based compensation | $5.2M | $4.5M | $680K | +15% |
| Working capital & other | $11.4M | $84.2M | −$72.8M | -86% |
| Operating cash flow | $95.4M | $98.2M | −$2.8M | -3% |
| Free cash flow (OCF − capex) | $86.9M | $93.3M | −$6.4M | -7% |
| Capital expenditures | $8.5M | $4.9M | $3.6M | +73% |
Questions
How much did Bio-Techne's revenue grow year over year in Q4 FY26?
Bio-Techne's revenue rose $4.2M (+1%) from $317M in Q4 FY25 to $321M in Q4 FY26. Gross margin 65.8% against 62.7% (+3.1 pts).